Advanced

Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader

Liedholm, Hans LU and Linné, Agneta Bjorck (2006) In Läkartidningen 103(18). p.1417-1426
Abstract
To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contributed. All published studies not included in the registration file were also included in the analysis. Data on glycaemic control, expressed as HbA1c, hypoglycaemia, and change in body weight were registered. Quality of life - a secondary endpoint infrequently investigated - was considered. All studies included a comparison with NPH insulin,... (More)
To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contributed. All published studies not included in the registration file were also included in the analysis. Data on glycaemic control, expressed as HbA1c, hypoglycaemia, and change in body weight were registered. Quality of life - a secondary endpoint infrequently investigated - was considered. All studies included a comparison with NPH insulin, incorporating both type 1 and type 2-diabetes. There was no consistent difference between the two insulin treatments regarding HbA1c, nor was there any evidence concerning differences regarding hypoglycaemia, except instances of mild nocturnal hypoglycaemia. These cases were not adequately reported, however. A small change in body weight in favour of insulin detemir was detected. No data on quality of life was identified. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Läkartidningen
volume
103
issue
18
pages
1417 - 1426
publisher
Swedish Medical Association
external identifiers
  • scopus:33745008625
ISSN
0023-7205
language
English
LU publication?
yes
id
bc933d6d-780b-48a4-958f-e45c9c8719dc (old id 156552)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16729454&dopt=Abstract
http://ltarkiv.lakartidningen.se/artNo31746
date added to LUP
2007-07-25 14:00:56
date last changed
2019-03-31 04:19:55
@article{bc933d6d-780b-48a4-958f-e45c9c8719dc,
  abstract     = {To investigate the evidence behind supposed advantages of insulin detemir over existing therapy (NPH insulin), we carried out a systematic review. We analysed the available documentation presented after registration of the drug by the European drug regulatory authority (EMEA) and approached the data presented at the authority's Internet site. Some data from Food and Drug Administraion (FDA) contributed. All published studies not included in the registration file were also included in the analysis. Data on glycaemic control, expressed as HbA1c, hypoglycaemia, and change in body weight were registered. Quality of life - a secondary endpoint infrequently investigated - was considered. All studies included a comparison with NPH insulin, incorporating both type 1 and type 2-diabetes. There was no consistent difference between the two insulin treatments regarding HbA1c, nor was there any evidence concerning differences regarding hypoglycaemia, except instances of mild nocturnal hypoglycaemia. These cases were not adequately reported, however. A small change in body weight in favour of insulin detemir was detected. No data on quality of life was identified.},
  author       = {Liedholm, Hans and Linné, Agneta Bjorck},
  issn         = {0023-7205},
  language     = {eng},
  number       = {18},
  pages        = {1417--1426},
  publisher    = {Swedish Medical Association},
  series       = {Läkartidningen},
  title        = {Insulin detemir har jämförts med NPH-insulin. Behandlingsstudier visar inga egentliga skillnader},
  volume       = {103},
  year         = {2006},
}